keyword
MENU ▼
Read by QxMD icon Read
search

bioresorbable vascular scaffold

keyword
https://www.readbyqxmd.com/read/28335892/hybrid-percutaneous-coronary-intervention-with-bioresorbable-vascular-scaffolds-in-combination-with-drug-eluting-stents-or-drug-coated-balloons-for-complex-coronary-lesions
#1
REVIEW
Akihito Tanaka, Richard J Jabbour, Satoru Mitomo, Azeem Latib, Antonio Colombo
Bioresorbable vascular scaffolds (BVS) have become an attractive option in the percutaneous coronary intervention field due to the potential advantages associated with the complete resorption process that occurs within a few years. However, current-generation BVS have several limitations including thicker struts, reduced radial strength, and limited expansion capability when compared with drug-eluting stents (DES). As a result, complex coronary disease often contains BVS-inappropriate/unfavorable segments...
March 27, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28330667/consequences-of-vascular-calcification-implications-for-bioresorbable-vascular-scaffolds
#2
EDITORIAL
Michael Joner, Erion Xhepa
No abstract text is available yet for this article.
March 10, 2017: JACC. Cardiovascular Imaging
https://www.readbyqxmd.com/read/28330651/serial-assessment-of-tissue-precursors-and%C3%A2-progression-of-coronary-calcification-analyzed-by-fusion-of-ivus-and-oct-5-year-follow-up-of-scaffolded-and-nonscaffolded-arteries
#3
Yaping Zeng, Hiroki Tateishi, Rafael Cavalcante, Erhan Tenekecioglu, Pannipa Suwannasom, Yohei Sotomi, Carlos Collet, Shaoping Nie, Hans Jonker, Jouke Dijkstra, Maria D Radu, Lorenz Räber, Dougal R McClean, Robert-Jan van Geuns, Evald H Christiansen, Therese Fahrni, Jacques Koolen, Yoshinobu Onuma, Nico Bruining, Patrick W Serruys
OBJECTIVES: The aim of this study was to assess calcium growth with fused grayscale intravascular ultrasound (IVUS), IVUS-virtual histology, and optical coherence tomography (OCT) from baseline to 5-year follow-up in patients treated with bioresorbable vascular scaffolds. BACKGROUND: IVUS and OCT have individual strengths in assessing plaque composition and volume. Fusion of images obtained using these methods could potentially aid in coronary plaque assessment...
March 10, 2017: JACC. Cardiovascular Imaging
https://www.readbyqxmd.com/read/28329198/long-term-serial-non-invasive-multislice-computed-tomography-angiography-with-functional-evaluation-after-coronary-implantation-of-a-bioresorbable-everolimus-eluting-scaffold-the-absorb-cohort-b-msct-substudy
#4
Yoshinobu Onuma, Carlos Collet, Robert-Jan van Geuns, Bernard de Bruyne, Evald Christiansen, Jacques Koolen, Pieter Smits, Bernard Chevalier, Dougal McClean, Dariusz Dudek, Stephan Windecker, Ian Meredith, Koen Nieman, Susan Veldhof, John Ormiston, Patrick W Serruys
Aims: Multimodality invasive imaging of the first-in-man cohort demonstrated at 5 years stable lumen dimensions and a low rate of major adverse cardiac events (MACE). However, the long-term non-invasive assessment of this device remains to be documented. The objective was to describe the 72-month multislice computed tomography (MSCT) angiographic and functional findings after the implantation of the second iteration of the fully resorbable everolimus-eluting polymeric scaffold. Methods and results: In the ABSORB Cohort B trial patients with non-complex de novo lesions were treated with second iteration bioresobable vascular scaffold (BVS)...
March 16, 2017: European Heart Journal Cardiovascular Imaging
https://www.readbyqxmd.com/read/28329070/paclitaxel-crystals-on-the-surface-of-a-bioresorbable-vascular-scaffold-visualized-by-optical-coherence-tomography-after-drug-eluting-balloon-angioplasty
#5
María López-Benito, Armando Pérez de Prado, Carlos Cuellas, Rodrigo Estévez, Felipe Fernández-Vázquez
No abstract text is available yet for this article.
February 27, 2017: European Heart Journal Cardiovascular Imaging
https://www.readbyqxmd.com/read/28320687/12-months-outcomes-after-bioresorbable-vascular-scaffold-implantation-in-patients-with-acute-coronary-syndromes-data-from-the-european-multicentre-ghost-eu-extended-registry
#6
Boris Schnorbus, Jens Wiebe, Davide Capodanno, Salvatore Brugaletta, Salvatore Geraci, Julinda Mehilli, Azeem Latib, Maciej Lesiak, Christoph Jensen, Alessio Mattesini, Thomas Münzel, Piera Capranzano, Carlo Di Mario, Christoph Naber, Aleksander Araszkiewicz, Antonio Colombo, Giuseppe Caramanno, Manel Sabate, Corrado Tamburino, Holger Nef, Tommaso Gori
AIMS: We report on the mid-term outcomes of patients undergoing percutaneous coronary intervention with bioresorbable vascular scaffolds (BVS) for the treatment of acute coronary syndromes (ACS) and compare with those of patients with stable coronary artery disease (sCAD). METHODS AND RESULTS: 1477 patients underwent implantation of one or more BVS (Absorb BVS; Abbott Vascular, Santa Clara, CA, USA) at 11 European centers and were included in the GHOST-EU registry...
March 21, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28317791/neoatherosclerosis-an-emerging-and-conceptually-unexpected-cause-of-very-late-bioresorbable-vascular-scaffold-failure
#7
Nick Hiltrop, Walter Desmet, Tom Adriaenssens, Johan Bennett
No abstract text is available yet for this article.
March 20, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28314675/a-hybrid-strategy-with-bioresorbable-vascular-scaffolds-and-drug-eluting-stents-for-treating-complex-coronary-lesions
#8
Richard J Jabbour, Alfonso Ielasi, Akihito Tanaka, Massimo Leoncini, Bernado Cortese, Giulietta Grigis, Satoru Mitomo, Damiano Regazzoli, Gaetano Di Palma, Claudio Rapetto, Maurizio Tespili, Antonio Colombo, Azeem Latib
BACKGROUND: Due to the inherent limitations of current generation BVSs, complex coronary artery disease often contains BVS unsuitable segments. Our aim was to assess the feasibility of a hybrid approach using bioresorbable vascular scaffolds (BVSs) and drug-eluting stents (DESs) for the treatment of complex coronary artery lesions not suitable for a scaffolding only approach. METHODS: A retrospective multicenter cohort analysis was performed on patients with complex de novo or in-stent restenosis lesions treated with a hybrid BVS (Absorb BVS, Abbott Vascular, Santa Clara, CA) and DES strategy...
March 8, 2017: Cardiovascular Revascularization Medicine: Including Molecular Interventions
https://www.readbyqxmd.com/read/28299676/bioresorbable-scaffolds-for-coronary-stenosis-when-and-how-based-upon-current-studies
#9
REVIEW
Alexandre Abizaid, J Ribamar Costa
PURPOSE OF REVIEW: First-generation bioresorbable scaffolds (BRS), largely represented by the poly-l-lactic acid (PLLA) ABSORB (Abbott Vascular, Temecula, Illinois, US), have demonstrated, in low to moderate lesion complexity, similar efficacy to current generation metallic drug-eluting stents. However, a trend toward more device thrombosis has been observed, especially when the scaffolds are used in off-label situations. In this review, we address the most relevant drawbacks of these devices and, based on the available scientific data, we visit the scenarios where there is more uncertainty about their indication, trying to identify the lesions/patients to whom this technology should be voided at its current stage of development...
March 2017: Current Cardiology Reports
https://www.readbyqxmd.com/read/28295999/fracture-with-the-newer-bioresorbable-vascular-scaffolds
#10
Mostafa Elwany, Gaetano Di Palma, Bernardo Cortese
Bioresorbable vascular scaffolds (BVS) are being increasingly used in complex, real-world lesions. The possibility of strut fractures is a rare entity with the use of drug eluting stents (DES), but has not yet been adequately described for the BVS technology. In this report, we present a case of scaffold fracture of DEsolve BVS (Elixir Medical Corporation, USA) that was diagnosed both angiographically and by optical coherence tomography(OCT). Scaffold fracture with the newer BVS is a new Achilles' heel in the BVS technology...
March 15, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28285939/restenosis-of-coronary-bioresorbable-vascular-scaffolds
#11
Fernando Alfonso, Marcos García-Guimaraes
No abstract text is available yet for this article.
March 9, 2017: Revista Española de Cardiología
https://www.readbyqxmd.com/read/28279311/antiplatelet-therapy-after-implantation-of%C3%A2-bioresorbable-vascular-scaffolds-a-review-of-the-published-data-practical-recommendations-and%C3%A2-future-directions
#12
REVIEW
Davide Capodanno, Dominick J Angiolillo
The introduction of bioresorbable vascular scaffolds (BVS) for clinical use has raised a number of questions on whether current dual-antiplatelet therapy (DAPT) recommendations after drug-eluting stent (DES) implantation, mostly deriving from data on second-generation DES, are also applicable to this completely different technology. This article aims to review the technical shortcomings of BVS-the most extensively studied fully bioresorbable coronary stent-and its contemporary rates of scaffold thrombosis, with a focus on recommendations for DAPT duration...
March 13, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28275974/early-disarticulation-of-a-bioresorbable-vascular-scaffold-an-underreported-consequence-of-repeat-imaging
#13
Joel P Giblett, Adam J Brown, Stephen P Hoole, Nick E J West
No abstract text is available yet for this article.
March 8, 2017: Cardiovascular Intervention and Therapeutics
https://www.readbyqxmd.com/read/28275942/bioresorbable-polymers-and-stent-devices
#14
REVIEW
Payam Dehghani
Percutaneous coronary interventions will never become obsolete, as evolution is inherent to interventional cardiology. Current drug-eluting platforms have appreciably improved their safety and efficacy profiles in different clinical settings compared to first-generation devices such that it is difficult to consider other alternatives. However, there is definite biological plausibility to consider devices with bioabsorbable polymers and/or scaffolds. It is also an undeniable fact that many patients, based on variety of belief systems, would prefer not to have a permanently implanted device...
February 2017: Current Treatment Options in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28262623/second-generation-magnesium-scaffold-magmaris-device-design-and-preclinical-evaluation-in-a-porcine-coronary-artery-model
#15
Ron Waksman, Philine Zumstein, Martin Pritsch, Eric Wittchow, Michael Haude, Capucine Lapointe-Corriveau, Guy Leclerc, Michael Joner
AIMS: The second-generation drug-eluting absorbable magnesium scaffold Magmaris, recently introduced for treatment of obstructive coronary atherosclerotic lesions, suggests a good safety profile, but preclinical assessment is important for predicting clinical performance. METHODS AND RESULTS: Ninety Magmaris scaffolds were implanted into non-diseased porcine and rabbit models. A bioresorbable vascular scaffold (Absorb) and the permanent drugeluting stent (Xience Xpedition) served as controls...
March 7, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28259663/bioresorbable-everolimus-eluting-vascular-scaffold-for-long-coronary-lesions-a-subanalysis-of-the-international-multicenter-ghost-eu%C3%A2-registry
#16
Salvatore Geraci, Hiroyoshi Kawamoto, Giuseppe Caramanno, Neil Ruparelia, Davide Capodanno, Tommaso Gori, Holger Nef, Julinda Mehilli, Maciej Lesiak, Christoph Naber, Carlo Di Mario, Piera Capranzano, Jens Wiebe, Aleksander Araszkiewicz, Stelios Pyxaras, Alessio Mattesini, Thomas Münzel, Corrado Tamburino, Antonio Colombo, Azeem Latib
OBJECTIVES: The authors sought to investigate 1-year outcomes in patients treated with bioresorbable everolimus-eluting vascular scaffolds (BVS) for "long coronary lesions." BACKGROUND: The present substudy derived from the GHOST-EU registry included 1,722 lesions in 1,468 consecutive patients, enrolled between November 2011 and September 2014 at 11 European centers. METHODS: The lesions were divided into 3 groups according to continuous BVS length: 1) shorter than 30 mm; 2) between 30 and 60 mm; and 3) longer than 60 mm...
February 24, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28258843/mid-to-long-term-outcome-of-patients-treated-with-everolimus-eluting-bioresorbable-vascular-scaffolds-data-of-the-bvs-registry-g%C3%A3-ttingen-predominantly-from-acs-patients
#17
Kristian Hellenkamp, Alexander Becker, Yannick D Gabriel, Gerd Hasenfuß, Mark Hünlich, Claudius Jacobshagen, Wolfgang Schillinger, Marco R Schroeter
BACKGROUND: Bioresorbable vascular scaffolds (BVS) are widely used in routine clinical practice. While previous studies reported acceptable short- to midterm outcome after BVS implantation, data on longer-term outcome are rare. METHODS: Patients treated with at least one Absorb®-BVS were consecutively enrolled. Follow-up data were assessed after 834.0 [769.0-1026.0] days. The primary device-oriented composite endpoint (DOCE) was defined as cardiovascular death, myocardial infarction (MI) and/or target lesion revascularization (TLR)...
May 1, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28254259/follow-up-of-coronary-artery-patency-after-implantation-of-bioresorbable-coronary-scaffolds-the-emerging-role-of-magnetic-coronary-artery-imaging
#18
REVIEW
Marco Zuin, Gianluca Rigatelli, Fiorenzo Scaranello, Massimo Rinuncini, Claudio Picariello, Katia D'Elia, Majlinda Fejzo, Loris Roncon
Bioresorbable vascular scaffolds (BVSs) represent the newest tool in the treatment of coronary artery disease (CAD). Conversely to the previous metal stents and thanks to the polylactate-based backbone, BVSs could be visualized by magnetic resonance imaging (MRI) without artifacts. These properties allow a potential non-invasive assessment of coronary artery patency after percutaneous coronary intervention (PCI), avoiding cardiac catheterization included iodine contrast and radiation exposure, and potentially more sophisticated imaging tool as the optical coherence tomography (OCT)...
February 7, 2017: Cardiovascular Revascularization Medicine: Including Molecular Interventions
https://www.readbyqxmd.com/read/28246060/predilation-sizing-and-post-dilation-scoring-in-patients-undergoing-everolimus-eluting-bioresorbable-scaffold-implantation-for-prediction-of-cardiac-adverse-events-development-and-internal-validation-of-the-psp-score
#19
Luis Ortega-Paz, Davide Capodanno, Tommaso Gori, Holger Nef, Azeem Latib, Giuseppe Caramanno, Carlo Di Mario, Christoph Naber, Maciej Lesiak, Piera Capranzano, Jens Wiebe, Julinda Mehilli, Aleksander Araszkiewicz, Stelios Pyxaras, Alessio Mattesini, Salvatore Geraci, Toru Naganuma, Antonio Colombo, Thomas Münzel, Manel Sabaté, Corrado Tamburino, Salvatore Brugaletta
AIMS: The aim of the study was to develop a scoring model to evaluate the quality of bioresorbable vascular scaffold (BVS) implantation and determine the model's usefulness in predicting adverse cardiac events. METHODS AND RESULTS: The implantation technique and clinical outcomes of 1,736 lesions treated with BVS were analysed using the GHOST-EU registry. Predilation, scaffold sizing, and post-dilation (PSP) were scored according to the hazard model derived from the weight of these variables...
March 2, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28218604/everolimus-eluting-bioresorbable-vascular-scaffold-for-treatment-of-complex-chronic-total-occlusions
#20
Jiang Ming Fam, Soledad Ojeda, Roberto Garbo, Azeem Latib, Alessio La Manna, Beatriz Vaquerizo, Marouane Boukhris, Georgios J Vlachojannis, Robert Jan van Geuns, Babu Ezhumalai, Hiroyoshi Kawamoto, Jors van der Sijde, Cordula Felix, Manuel Pan, Roberta Serdoz, Giacomo Giovanni Boccuzzi, Marcella De Paolis, Gennaro Sardella, Corrado Tamburino, Pieter C Smits, Carlo Di Mario, Ashok Seth, Antonio Serra, Antonio Colombo, Patrick Serruys, Alfredo R Galassi, Felix Zijlstra, Nicolas M van Mieghem, Roberto Diletti
AIMS: Bioresorbable vascular scaffolds (BVS) represent a novel therapeutic option for the treatment of coronary artery diseases. The objective of this study is to evaluate the feasibility of BVS implantation in complex chronic total occlusions (CTO). METHODS AND RESULTS: The present report is a multi-centre registry evaluating results after BVS deployment in challenging CTO lesions defined as J-CTO score≥2 (difficult or very difficult). A total of 105 patients were included in the present analysis...
February 21, 2017: EuroIntervention
keyword
keyword
74350
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"